PRESS STATEMENT: FDA Approves Praluent, New Cholesterol-Lowering Treatment

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but it’s price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years.”

Read more

PRESS STATEMENT: New Report Shows Medicare Spending Increase Driven By Specialty Drug Prices

PRESS STATEMENT: New Report Shows Medicare Spending Increase Driven By Specialty Drug Prices

Read more

PRESS STATEMENT: New Report Shows Hepatitis C Drugs Have Costly Impact on California

Exorbitant price tags for specialty medications are taking a serious financial toll on state budgets. A new analysis released yesterday from the California Association of Health Plans (CAHP) shows that treating only 10 percent of 175,000 patients in state-funded health care programs with just three hepatitis C medications would cost California roughly $1-2 billion.

Read more

PRESS STATEMENT: Survey Finds Early Primary State Voters Looking for Action on Prescription Drug Prices

A recent study of over 2,500 voters in Iowa, South Carolina and New Hampshire found that prescription drug prices are becoming a hot political issue in these early primary states. The study was conducted by Morning Consult on behalf of the Campaign for Sustainable Rx Pricing.

Read more